HB2462, titled Dillon’s Law, amends the Illinois Epinephrine Injector Act to broaden and modernize the state’s rules for access to epinephrine in emergencies. The bill replaces the term “epinephrine injector” with “epinephrine delivery system” throughout the Act, which expands the definition to include any FDA-approved form of epinephrine used to treat life-threatening allergic reactions, including devices beyond traditional auto-injectors. It also adds a new category of “authorized individual,” meaning a person who has completed the required anaphylaxis training program.
The bill allows health care practitioners to prescribe epinephrine delivery systems not only to authorized entities, but also to authorized individuals, and it permits pharmacists and practitioners to dispense them under those prescriptions. It authorizes a Department of Public Health health care provider to issue a statewide standing order for dispensing epinephrine delivery systems for use by trained authorized individuals and by employees or agents of authorized entities. The bill also requires training on recognizing anaphylaxis, administering epinephrine, and demonstrating competency, and it directs the Department to approve and list training programs. A new liability-limitation section protects authorized individuals acting in good faith from civil damages, except in cases of willful and wanton misconduct.
HB2462 also updates the operational rules for stocking and using undesignated epinephrine delivery systems in places where allergens may be present, including schools-related transportation, camps, colleges, day care facilities, youth sports leagues, amusement parks, restaurants, sports arenas, and workplaces. Authorized entities and individuals may stock supplies, and trained personnel may provide or administer epinephrine to someone believed to be experiencing anaphylaxis, even if that person does not have a prescription or prior allergy diagnosis. The bill further clarifies that using an undesignated epinephrine delivery system under the Act is not the practice of medicine and does not limit the amount that may be carried or maintained.
The overall sentiment appears strongly supportive and noncontroversial. The bill passed the House 114-0 and later passed a Senate motion 57-0, indicating unanimous bipartisan approval in both chambers. The lack of committee transcript material suggests there was little recorded public dispute or extended debate.
The main policy point of discussion embedded in the text is the expansion of who may receive, stock, and administer epinephrine, along with the shift from a device-specific framework to a broader “delivery system” framework. The new liability protection for authorized individuals is another notable feature, as it reduces legal risk for lay responders acting in good faith. Any potential concern would likely center on training adequacy, emergency-use safeguards, and the scope of immunity, but the voting record suggests those issues did not generate significant opposition.
The bill amends the Epinephrine Injector Act, codified at 410 ILCS 27/5, 10, 15, 20, and adds new Section 25. It expands statutory terminology from “epinephrine injector” to “epinephrine delivery system,” broadens who may be prescribed and trained to use epinephrine, authorizes statewide standing orders, and creates a civil liability shield for authorized individuals acting in good faith. It affects health care practitioners, pharmacists, the Illinois Department of Public Health, authorized entities such as camps, schools-related transportation providers, restaurants, workplaces, and other venues where allergens may be present, as well as trained laypersons who may respond to anaphylaxis emergencies.
The bill’s sentiment is overwhelmingly positive. It advanced with unanimous votes in both chambers, 114-0 in the House and 57-0 in the Senate motion, suggesting broad bipartisan agreement that the measure improves emergency allergy response and access to epinephrine. No committee transcript was provided, and there is no indication of organized opposition or significant amendment controversy in the available record.
The principal points that could generate contention are the expansion of authority to trained laypersons, the use of a statewide standing order, and the new liability limitation for good-faith emergency responders. Some stakeholders might question whether the training requirements are sufficient, whether broader access could create implementation or storage issues for authorized entities, or whether immunity is too broad. However, the unanimous votes indicate that any such concerns were either resolved or not politically significant in the bill’s passage.